Literature DB >> 25973113

Dedifferentiation-like progression of breast carcinoma: report of a case showing transition from luminal-type carcinoma to triple-negative carcinoma with myoepithelial features.

Shogo Tajima1, Kenji Koda2.   

Abstract

Certain genetic events that occur at various stages of carcinogenesis can result in phenotypic changes. In breast carcinoma, these changes may occur either in situ, at the primary invasive site, or at a distant metastatic site. This report presents a case of dedifferentiation-like progression of breast carcinoma showing transition from luminal-type carcinoma to triple-negative carcinoma (i.e. negative for estrogen receptor, progesterone receptor, and HER2) with myoepithelial features. An 87-year-old woman was referred to us from another hospital for surgery. Preoperative ultrasonography revealed a mass measuring 16 × 12 × 8 mm. Following partial mastectomy, gross examination revealed a whitish tumor on the cut surface measuring 15 × 10 × 8 mm. Histopathological investigation revealed a predominant high-grade carcinoma containing some short spindle-shaped cells and expressing p63, muscle-specific actin, and alpha smooth muscle actin. The tumor also showed decreased expression of pan-cytokeratin and increased expression of vimentin on immunohistochemistry. Estrogen receptor was not detected by immunostaining. A high Ki-67 labeling index and diffuse nuclear accumulation of p53 were observed in the high-grade carcinoma. In the peripheral area, low-grade carcinoma with estrogen receptor expression was observed, but appeared displaced by the high-grade carcinoma. The high-grade carcinoma exhibiting myoepithelial carcinoma-like morphology and molecular phenotype was deemed to be carcinoma showing dedifferentiation-like changes arising from the peripherally situated pre-existing low-grade carcinoma. Thus, follow-up ought to be mandatory, considering the presumably aggressive nature of the predominant carcinoma showing dedifferentiation-like changes in this case.

Entities:  

Keywords:  Breast; carcinoma; dedifferentiation; luminal-type; myoepithelial features

Mesh:

Substances:

Year:  2015        PMID: 25973113      PMCID: PMC4396209     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  10 in total

1.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification.

Authors:  A García Fernández; C Chabrera; M García Font; M Fraile; J M Lain; S Gónzalez; I Barco; C González; J Torres; M Piqueras; L Cirera; E Veloso; A Pessarrodona; N Giménez
Journal:  Clin Transl Oncol       Date:  2014-10-01       Impact factor: 3.405

3.  Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?

Authors:  Carolien H M van Deurzen; Andrew H S Lee; Muhammad S Gill; Marian B E Menke-Pluijmers; Agnes Jager; Ian O Ellis; Emad A Rakha
Journal:  J Pathol       Date:  2011-04-01       Impact factor: 7.996

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Dedifferentiated acinic cell carcinoma of the parotid gland with myoepithelial features.

Authors:  Simonetta Piana; Alberto Cavazza; Corrado Pedroni; Rosa Scotti; Luigi Serra; Giorgio Gardini
Journal:  Arch Pathol Lab Med       Date:  2002-09       Impact factor: 5.534

Review 6.  Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?

Authors:  Ping Tang; Kristin A Skinner; David G Hicks
Journal:  Diagn Mol Pathol       Date:  2009-09

7.  Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Authors:  Maggie C U Cheang; David Voduc; Chris Bajdik; Samuel Leung; Steven McKinney; Stephen K Chia; Charles M Perou; Torsten O Nielsen
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

Review 8.  Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features.

Authors:  Jennifer Leidy; Ashraf Khan; Dina Kandil
Journal:  Arch Pathol Lab Med       Date:  2014-01       Impact factor: 5.534

9.  BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.

Authors:  Gemma Molyneux; Felipe C Geyer; Fiona-Ann Magnay; Afshan McCarthy; Howard Kendrick; Rachael Natrajan; Alan Mackay; Anita Grigoriadis; Andrew Tutt; Alan Ashworth; Jorge S Reis-Filho; Matthew J Smalley
Journal:  Cell Stem Cell       Date:  2010-09-03       Impact factor: 24.633

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

  10 in total
  1 in total

1.  Evaluation of a developmental hierarchy for breast cancer cells to assess risk-based patient selection for targeted treatment.

Authors:  Sarah A Bliss; Sunirmal Paul; Piotr W Pobiarzyn; Seda Ayer; Garima Sinha; Saumya Pant; Holly Hilton; Neha Sharma; Maria F Cunha; Daniel J Engelberth; Steven J Greco; Margarette Bryan; Magdalena J Kucia; Sham S Kakar; Mariusz Z Ratajczak; Pranela Rameshwar
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.